Current stock page

Catalysts

ARQT Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ARQTArcutis Biotherapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$28.26+$0.73 (+2.65%)

Latest quote

  • Momentum
    76
  • Value
    65
  • Quality
    76
  • Risk resilience
    46
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 24, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 69/100

Momentum 76/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 16.31%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 76/100AIQ Edge 8/10 Strong Relative Position
Beat rate
75%
6 of 8 reported periods
Average surprise
+34.6%
Across covered historical reports
Latest result
-66.7%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$0.18$0.06-66.7%$142.59M$143.92M
Aug 5, 2026—$0.06$0.11+99.7%$118.85M$129.86M
May 6, 2026—-$0.02-$0.09-350.0%$103.68M$105.4M
Feb 25, 2026—$0.03$0.13+333.3%$113.06M$129.5M
Oct 28, 2025—-$0.10$0.06+160.0%$110.79M$99.22M
Aug 6, 2025—-$0.18-$0.13+27.8%$80.63M$81.5M
May 6, 2025—-$0.21-$0.20+4.8%$72.7M$65.85M
Feb 25, 2025—-$0.28-$0.09+67.9%$60.52M$71.36M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
7
Buy
1
Hold
12-month analyst target
$42.75
+51.27% versus current price
Based on 8 analyst observations. Targets are estimates, not predictions.
Low target
$39.00
+38.00% vs latest price
Average target
$42.75
+51.27% vs latest price
High target
$48.00
+69.85% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 24, 2027

Next known earnings or reporting date.

EPS estimate$0.21

Current analyst expectation for the upcoming report.

Revenue estimate$163.07M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score76

Where event reaction would show up first.

AIQ score69/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
8
Average target
$42.75
Target upside
51.27%
Target range
$39.00 - $48.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
1
seekingalpha.com · Nov 9, 2026

Arcutis Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ARQT) 2026-11-09

2026-11-09. The following slide deck was published by Arcutis Biotherapeutics, Inc.

gurufocus.com · Nov 7, 2026

Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to $143.9 Million as Guidance Raised and Pipeline Expands

Release Date: November 04, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Net product

seekingalpha.com · Nov 5, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call November 4, 2026 4:30 PM ESTCompany ParticipantsBrian Schoelkopf - Head of Investor RelationsTodd...

zacks.com · Nov 4, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -64.71% and +1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

zacks.com · Oct 28, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Open full news and sentiment

ARQT Catalysts FAQ

What are the next catalysts for ARQT stock?

ARQT's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ARQT stock?

Upcoming events that could move ARQT include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ARQT's next earnings report affect the stock?

ARQT's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ARQT stock higher?

ARQT could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ARQT stock?

ARQT could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.